Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enbridge

Realty Income Corp

AbbVie is a Dividend King that's poised for future growth. Enbridge offers an ultra-high dividend yield and is expanding into more areas of the energy sector.

3 High-Yield Stocks to Buy Now That Have Increased Their Dividends for 25 Years or More

Merck

Novo Nordisk

Keytruda, Humira, and Ozempic generated a combined $53 billion in sales last year. The companies that make these drugs generate a lot of their sales from them.

These 3 Healthcare Companies Had the Top-Selling Drugs Last Year

Prologis

Verizon

AbbVie enables retirees to profit from both its dividend payouts and its promising growth opportunities. Verizon has a safe high-yielding dividend, which the company has been growing steadily in recent years.

3 High-Yielding Dividend Growth Stocks That Retirees Can Rely On for Recurring Income

Kenvue

PepsiCo

Investors looking for a respite from the ongoing market volatility may want to seek out dividend-paying stocks. The benefit of these stocks is that they give you an opportunity for reliable income today and into the future.

Lock in Gains: 3 Dividend Stocks Poised to Boost Payouts Soon

Visa

Everything looked like it was coming undone last week. As recession fears gripped the market, the S&P 500 tumbled 3% in a single day.

The 3 Best Stocks to Buy to Survive Another S&P 500 Crash

Eli Lilly

Pfizer

Here we discuss three drugmakers, Eli Lilly and Company (LLY), Pfizer (PFE) and AbbVie (ABBV), following their increase in sales and earnings guidance for 2024.

3 Big Drug Stocks to Watch on Raised 2024 Earnings & Sales View

24/7 Wall St. Insights Stocks that consistently raise their dividends offer investors huge total return potential.

Prediction: Abbvie's Dividend Payouts Will Increase in 2025

ATLANTA--(BUSINESS WIRE)---- $ABBV #21_million_Americans_afflicted_with_MDD--Alzamend Neuro Partners with Mass. General Hosp. for Phase II Clinical Trial of AL001, a Next-Generation Lithium Drug for Major Depressive Disorder.

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Major Depressive Disorder

Bristol-Myers

Gilead Sciences

AbbVie offers reliable income and solid growth prospects. Bristol Myers Squibb is a stable dividend stock to buy and hold.

3 Stocks Retirees Should Absolutely Love

Apple

Amgen

Ares Capital

Home Depot

Coca-Cola

Lockheed Martin

Microsoft

Vici Properties

Times of higher uncertainty and elevated market volatility can provide investors with excellent opportunities to start building a dividend portfolio. The dividend portfolio I will present in today's article provides investors with broad diversification across sectors, with no sector accounting for more than 18% of the overall portfolio. This dividend portfolio delivers a Weighted Average Dividend Yield [TTM] of 3.90% and a 5-year Weighted Average Dividend Growth Rate of 8.69%.

Building A $100,000 Dividend Portfolio With 3 ETFs And 3 Stocks

American Tower

10,000 boomers are reaching retirement age every day. The 4% rule for retirement withdrawals may not always work due to sequence risk and market fluctuations. Building a dividend income snowball can provide a more stable retirement income, with 2 high-yielding recession-proof stock picks recommended.

2 High Yielding Recession Proof Dividend Picks For A Massive Income Snowball

Seasoned investors tend to closely follow the ups and downs of the market.

3 Passive Income Dividend Stocks To Buy Now

UnitedHealth Group

The S&P 500 is down a staggering $3.2 trillion in the market implosion since mid-July. But some investors are dodging the pain.

13 Stocks Make Investors $200 Billion Richer As The Rest Collapse

ATLANTA--(BUSINESS WIRE)---- $ABBV #7_milliion_Americans_afflicted_with_Bipolar_disorder--Alzamend Neuro Partners with Mass. General Hosp. for Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate for BD.

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, involving Patients with Bipolar Disorder

AstraZeneca's (AZN) key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Farxiga should drive sales. Its pipeline is huge, with several candidates having blockbuster potential.

How Should You Play AstraZeneca (ABBV) After Q2 Beat, View Raise?

ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro Partners with Massachusetts General Hosp. for Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate.

Alzamend Neuro Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, involving Patients with Alzheimer's Disease

The S&P 500 index came close to correction territory on Aug. 2, after falling about 5.7% from a peak it reached in mid-July. With drugs that some of us can't live without, Bristol Myers Squibb hasn't lowered its dividend payment in 25 years.

Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.

Antero Midstream Partners

CME Group

The tech rally is losing steam as economic indicators, including rising unemployment and weak manufacturing data, suggest increasing recession risks. Investors are shifting focus from high-growth tech to value stocks, driven by concerns over valuation and a slowing economic outlook. In this uncertain environment, finding quality investments with solid balance sheets and growth potential is key to navigating potential market turbulence.

High-Yield Harvest: 3 Of My Favorite Dividend Stocks For What's Next

Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff, quite well and looks set to return to robust growth next year.

Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise?

Cerevel Therapeutics Holdings Inc

Cerevel's clinical-stage assets complement AbbVie's emerging neuroscience pipeline and leading on-market brands in psychiatry, migraine and Parkinson's disease Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia Cerevel is a strong strategic fit for AbbVie and has potential to meaningfully impact revenue into the next decade AbbVie reaffirms previously issued 2024 full-year adjusted diluted EPS guidance range of $10.71-$10.91; reaffirms previously issued third-quarter adjusted diluted EPS guidance range of $2.92-$2.96 NORTH CHICAGO, Ill. , Aug. 1, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE).

AbbVie Completes Acquisition of Cerevel Therapeutics

Abbott Labs

Long-term outlook is crucial in investing, short-term gains may be attractive but can turn out to be bad if continued. AbbVie is a successful example of a newly-listed company that has turned out to be a great long-term investment. Kenvue and Sila Realty Trust are two newly-listed companies that could potentially reward investors similarly to AbbVie.

2 Stocks With Potential To Become Great Long-Term Investments

ATLANTA--(BUSINESS WIRE)---- $ABBV #Alzamend--Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement.

Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement

ASML Hld

Domino's Pizza

Netflix

Taiwan Semiconductor Manufacturing

Understanding companies' fundamentals is vital for evaluating top stocks to buy. It helps one to make sharp investment decisions based on financial health, growth potential and competitive advantages.

7 Stocks Set for a Major Bull Run

Growth stocks, known for rapid expansion and solid market positions, have outperformed for years. Despite not being market leaders yet, they possess the potential to dominate.

3 Powerhouse Growth Stocks to Load Up On During This Bull Market Cycle

AbbVie NYSE: ABBV was among the pharma companies worst positioned for a patent cliff that has come and gone. However, management's lean toward diversifying away from Humira and into a broader range of treatments has more than paid off.

News for AbbVie Stock (ABBV)